EVTCY - EVTCY STOCK NEWS

Evotec SE has entered a strategic collaboration with Janssen Biotech, Inc. to develop innovative immune-based therapies for oncology. This partnership, facilitated by Johnson & Johnson Innovation, allows Evotec to leverage its integrated discovery and development capabilities. The collaboration includes an undisclosed upfront payment, potential research and commercial milestones exceeding US$ 350 million, and tiered royalties on developed products. While Janssen will lead the clinical development, Evotec will focus on pre-clinical R&D and manufacturing.

Evotec SE has expanded its collaboration with Bristol Myers Squibb, adding two new drug discovery projects and designating a target-based program for development. This progress triggers total payments of US$ 26 million to Evotec. The collaboration, initiated in December 2016, aims to find disease-modifying treatments for neurodegenerative diseases, addressing a significant unmet medical need. Dr. Cord Dohrmann emphasized the ongoing success and productivity of this six-year partnership.

Evotec SE, a leading life science company, reported a 19% revenue increase to €510.8 million for the first nine months of 2022, despite lower milestone payments compared to 2021. The base business grew by 27% to €502.7 million. Adjusted EBITDA decreased to €44.6 million due to high expansion costs and inflated energy prices. The company also announced multiple drug discovery agreements and launched its multi-omics data analysis platform PanHunter. The full-year revenue outlook remains unchanged, targeting between €715-735 million.

Evotec SE announced the completion of its acquisition of Central Glass Germany GmbH from Central Glass Co. Ltd. This strategic move enhances Evotec's drug substance manufacturing capacity, particularly focusing on rare diseases and precision therapeutics. The facility, located in Halle/Westphalia, Germany, is now operational and employs around 60 experts in chemical manufacturing. Evotec plans significant investments to establish this site as a leading center for rare disease drug substance manufacturing in Europe.

Evotec SE presented a transformative update on biologics manufacturing at its Capital Markets Day, focusing on global access to biotherapeutics. The company’s subsidiary, Just - Evotec Biologics, showcased its integrated AI/ML-based technologies, emphasizing a paradigm shift in the industry. Significant highlights include a $49.9 million contract with the U.S. Department of Defense for monoclonal antibody prototypes and the groundbreaking of a new manufacturing facility in Toulouse, France. CEO Dr. Werner Lanthaler underscored the need for modernized manufacturing to enhance accessibility to essential therapies.

Evotec SE has launched a new translational partnership named Extend in collaboration with CDP Venture Capital and Angelini Ventures. This initiative aims to enhance drug discovery efforts by forming partnerships with esteemed academic institutions across Italy. The Extend initiative seeks to translate innovative academic research into actionable data, facilitating the creation of spin-off companies. Key institutions involved include Ospedale San Raffaele and several universities from Milan, Florence, and Padua. This venture is part of Evotec's broader strategy to foster innovation and accelerate commercialization of promising therapeutics.

Evotec has partnered with Hannover Medical School to create a molecular patient database for Sjogren's syndrome and systemic lupus erythematosus. The collaboration aims to enhance disease understanding through a unique longitudinal PanOmics database by analyzing biospecimens from hundreds of patients. Evotec will commercially exploit the data, while MHH will use it for academic research. This partnership could facilitate the development of personalized therapies for autoimmune diseases, addressing unmet medical needs.

Evotec SE launched its PanOmics data analysis platform, PanHunter, at Bio-IT World on October 18, 2022. This software-as-a-service (SaaS) product aims to empower scientists by providing comprehensive access to vast PanOmics data sets, accelerating R&D processes and improving drug discovery success rates. With a significant increase in publicly available PanOmics data, PanHunter is designed to stratify patient populations and predict drug efficacy and toxicity, marking a notable advancement in data-driven medicine.

Evotec and Toronto Innovation Acceleration Partners (TIAP) have expanded their LAB150 partnership to include Amgen as a strategic partner, committing a combined investment of US$ 14 million. This collaboration aims to enhance the development of Canada's life science companies by streamlining the transition from academic research to market-ready products. LAB150 has evaluated over 150 projects and currently supports 10 projects. Amgen will provide financial backing and mentorship to these initiatives, accelerating commercialization efforts and fostering innovation in the sector.